Tempest Therapeutics, Inc. — Director's Dealing 2019

Jan 17, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Millendo Therapeutics, Inc. (MLND)
CIK: 0001544227
Period of Report: 2019-01-15

Reporting Person: HOWE JOHN P MD (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-15	Stock Option (right to buy)	$8.80	A	6000	Acquired	2029-01-14	Common Stock (6000)	Direct

Footnotes

F1: One hundred percent (100%) of the shares subject to this option will vest on January 15, 2020, subject to the Reporting Person continuing to provide service through such date.